好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Rimegepant for the Prevention of Episodic Migraine in Adults with Prior Inadequate Response to Oral Preventatives: Results from a 12-week Open-label Extension Phase of a Randomized, Placebo-controlled Trial
Headache
P10 - Poster Session 10 (8:00 AM-9:00 AM)
15-011

Report findings from the open-label extension (OLE) phase of a multinational, randomized, placebo-controlled trial evaluating rimegepant for the prevention of episodic migraine in participants with a history of inadequate response to oral preventive medications (OPMs).
Many patients have found inadequate benefit from prior OPMs due to lack of efficacy, intolerance, or contraindication.
Participants with 4–14 monthly migraine days, <15 monthly headache days (<7 non-migraine), and documented history of inadequate response to 2–4 categories of OPM were enrolled. Following 12 weeks of randomized double-blind treatment (DBT) with rimegepant 75 mg orally disintegrating tablet (ODT) or placebo once every other day (EOD), participants entered an OLE phase to receive 12 weeks of rimegepant 75 mg EOD. Other preventive medications were not permitted.
At entry to the OLE phase, demographics and clinical characteristics were balanced across the 301 participants who previously received rimegepant and the 294 who received placebo as DBT. During the OLE phase, a mean of 14 ODTs were taken/month in both DBT groups. After 12 weeks of open-label (OL) rimegepant (Week 24 of the trial), change from baseline in patient-reported outcomes showed participants who received placebo as DBT achieved similar benefit as those on rimegepant since the start of the trial. During the OLE phase, 38.2% of participants had ≥1 adverse event (AE), including 6.6% related to rimegepant and 1.0% leading to rimegepant discontinuation. The three most common AEs were nasopharyngitis, influenza, and upper respiratory tract infection; the majority of AEs were mild or moderate in intensity. The safety profile of OL rimegepant was comparable across DBT groups and with previous trial findings.

Rimegepant is well tolerated and reduces overall disease burden when taken for the prevention of migraine in participants with a documented history of prior inadequate response to OPMs. NCT05518123
Authors/Disclosures
Robert Fountaine
PRESENTER 		Robert Fountaine has received personal compensation for serving as an employee of Pfizer, Inc.. Robert Fountaine has or had stock in Pfizer, Inc.Robert Fountaine has or had stock in Viatris, Inc.
Patricia Pozo-Rosich, MD, PhD Dr. Pozo-Rosich has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Pozo-Rosich has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Pozo-Rosich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Pozo-Rosich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Pozo-Rosich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Organon. Dr. Pozo-Rosich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dr. Reddy's. Dr. Pozo-Rosich has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sociedad Española Neurologia.
Jose Gien-Lopez, MD Dr. Gien-Lopez has nothing to disclose.
Pawel Lisewski (Tricals) No disclosure on file
Ayse Neslihan Aslan, MD Dr. Aslan has received personal compensation for serving as an employee of Pfizer. Dr. Aslan has stock in Pfizer Inc.
Harpreet Seehra, BSc(Hons), MSc Ms. Seehra has stock in Pfizer.
Alexandra Thiry, PhD Dr. Thiry has received personal compensation for serving as an employee of Pfizer. Dr. Thiry has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Dr. Thiry has stock in Pfizer. Dr. Thiry has stock in Biohaven Pharmaceuticals.
Lucy Abraham (Pfizer R&D UK Ltd) Lucy Abraham has received personal compensation for serving as an employee of Pfizer R&D UK Ltd. Lucy Abraham has stock in Pfizer R&D UK Ltd.
Luz M. Ramirez, MD Dr. Ramirez has received personal compensation for serving as an employee of Pfizer.
Terence Fullerton, PharmD (Pfizer Global Product Development) Dr. Fullerton has received personal compensation for serving as an employee of Pfizer. Dr. Fullerton has stock in Pfizer.